Brokerages Set Xenon Pharmaceuticals Inc. (NASDAQ:XENE) PT at $77.20

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) has earned a consensus recommendation of “Buy” from the seventeen ratings firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, fourteen have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $77.20.

Several equities research analysts recently weighed in on XENE shares. Bank of America reaffirmed a “buy” rating on shares of Xenon Pharmaceuticals in a research note on Monday, March 9th. Wells Fargo & Company reaffirmed an “overweight” rating and set a $69.00 target price on shares of Xenon Pharmaceuticals in a research note on Sunday, May 10th. Guggenheim reaffirmed a “buy” rating and set a $90.00 target price on shares of Xenon Pharmaceuticals in a research note on Monday, March 9th. Royal Bank Of Canada upped their target price on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “outperform” rating in a research note on Friday, May 8th. Finally, Wedbush lowered their price target on shares of Xenon Pharmaceuticals from $64.00 to $63.00 and set an “outperform” rating for the company in a report on Monday, March 16th.

Xenon Pharmaceuticals Stock Up 0.7%

Shares of XENE opened at $60.13 on Thursday. Xenon Pharmaceuticals has a fifty-two week low of $30.00 and a fifty-two week high of $63.95. The firm’s 50 day moving average price is $54.76 and its 200 day moving average price is $49.83. The company has a market cap of $5.81 billion, a P/E ratio of -12.79 and a beta of 0.62.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, hitting the consensus estimate of ($1.17). During the same quarter in the previous year, the company earned ($0.83) EPS. Research analysts forecast that Xenon Pharmaceuticals will post -4.92 earnings per share for the current year.

Insider Activity at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, Director Gary Patou sold 1,322 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $70,251.08. Following the completion of the transaction, the director owned 24,896 shares in the company, valued at $1,322,973.44. The trade was a 5.04% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Gillian Cannon sold 1,190 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $63,236.60. Following the transaction, the director owned 1,455 shares of the company’s stock, valued at $77,318.70. This trade represents a 44.99% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 4.07% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Cinctive Capital Management LP boosted its stake in Xenon Pharmaceuticals by 1.1% during the 4th quarter. Cinctive Capital Management LP now owns 23,317 shares of the biopharmaceutical company’s stock worth $1,045,000 after purchasing an additional 263 shares during the period. State of Wyoming boosted its stake in Xenon Pharmaceuticals by 30.4% during the 4th quarter. State of Wyoming now owns 1,501 shares of the biopharmaceutical company’s stock worth $67,000 after purchasing an additional 350 shares during the period. Quarry LP boosted its stake in Xenon Pharmaceuticals by 25.0% during the 3rd quarter. Quarry LP now owns 2,500 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 500 shares during the period. Altfest L J & Co. Inc. boosted its stake in Xenon Pharmaceuticals by 6.5% during the 4th quarter. Altfest L J & Co. Inc. now owns 8,232 shares of the biopharmaceutical company’s stock worth $369,000 after purchasing an additional 501 shares during the period. Finally, Royal Bank of Canada boosted its stake in Xenon Pharmaceuticals by 0.7% during the 1st quarter. Royal Bank of Canada now owns 90,387 shares of the biopharmaceutical company’s stock worth $5,255,000 after purchasing an additional 630 shares during the period. Institutional investors and hedge funds own 95.45% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.